市場調查報告書

IgG4相關疾病:2028年前的流行病學預測

IgG4-Related Disease - Epidemiology Forecast to 2028

出版商 DelveInsight Business Research LLP 商品編碼 905939
出版日期 內容資訊 英文 81 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
IgG4相關疾病:2028年前的流行病學預測 IgG4-Related Disease - Epidemiology Forecast to 2028
出版日期: 2019年08月01日內容資訊: 英文 81 Pages
簡介

本報告提供全球IgG4相關疾病的相關調查,提供疾病的背景及概要,患者人口,美國·德國·法國·義大利·西班牙·英國·日本的7個國家各國流行病學等資訊。

目錄

第1章 重要的洞察

第2章 疾病的背景及概要:IgG4相關疾病

  • 簡介
  • 免疫球蛋白
  • 臨床症狀
  • 病理學的機制
  • 症狀
  • 器官系統參與的臨床特徵
  • 病理生理學
  • IgG4相關疾病的病因
  • 診斷

第3章 流行病學及患者人口

  • 主要調查結果
  • 主要7個國家的患者總數
  • 主要7個國家的整體診斷患者數

第4章 IgG4相關疾病:各國流行病學

  • 美國
    • 假設及根據
    • 盛行率
    • 確診的盛行率
    • 性別的盛行率
    • 自體免疫性胰炎(AIP)的盛行率
  • 歐洲主要5國
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第5章 附錄

  • 報告方法

第6章 DelveInsight的服務內容

第7章 免責聲明

第8章 關於DelveInsight

目錄
Product Code: DIEI0370

DelveInsight's 'IgG4-Related Disease-Epidemiology Forecast to 2028' report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of IgG4-Related Disease in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028

IgG4-Related Disease Epidemiology

The IgG4-Related Disease epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The epidemiology data for IgG4-Related Disease are studied through all possible division to give a better understanding of the disease scenario in the 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports, and views of key opinion leaders.

IgG4-Related Disease Epidemiology Segmentation

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

The disease epidemiology covered in the report is segmented by:

  • Prevalent Population of IgG4-Related Disease
  • Diagnosed Prevalent Population of IgG4-Related Disease
  • Gender-specific Prevalent Population of IgG4-RD
  • Diagnosed Prevalent Population of Autoimmune Pancreatitis (AIP)

According to DelveInsight, the total diagnosed prevalent cases of IgG4-Related Disease were 204,818 in 2017 in the 7MM, which might increase by 2028.

Report Scope

  • The report covers a detailed overview of IgG4-Related Disease explaining its causes, symptoms, classification, pathophysiology, and diagnosis and treatment patterns.
  • The report provides the insight about the historical and forecasted patient pool for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of IgG4-Related Disease.
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.

Key strengths

  • 10 Year Forecast of IgG4-Related Disease epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of IgG4-Related Disease
  • Prevalent Cases according to the segmentation

Key assessments

  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Disease Background and Overview: IgG4-Related Disease

  • 2.1. Introduction
  • 2.2. Immunoglobulins
  • 2.3. Clinical Manifestations
  • 2.4. Pathophysiological Mechanisms
  • 2.5. Symptoms
  • 2.6. Clinical Features of Organ System Involvement
  • 2.7. Pathophysiology
  • 2.8. Pathogenesis of IgG4-related disease
  • 2.9. Diagnosis

3. Epidemiology and Patient Population

  • 3.1. Key Findings
  • 3.2. 7MM IgG4-Related Disease Total Patient Population
  • 3.3. 7MM IgG4-Related Disease Total Diagnosed Patient Population

4. Country Wise-Epidemiology of IgG4-Related Disease

  • 4.1. United States
    • 4.1.1. Assumptions and Rationale
    • 4.1.2. IgG4-Related Disease (IgG4-RD) Prevalent Population in the United States
    • 4.1.3. IgG4-Related Disease (IgG4-RD) Diagnosed Prevalent Population in the United States
    • 4.1.4. IgG4-RD Gender-specific Prevalent Population in the United States
    • 4.1.5. Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in the United States
  • 4.2. EU5 Countries
    • 4.2.1. Assumptions and Rationale
  • 4.3. Germany
    • 4.3.1. IgG4-Related Disease (IgG4-RD) Prevalent Population in Germany
    • 4.3.2. IgG4-Related Disease (IgG4-RD) Diagnosed Prevalent Population in Germany
    • 4.3.3. IgG4-RD Gender-specific Prevalent Population in Germany
    • 4.3.4. Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in Germany
  • 4.4. France
    • 4.4.1. IgG4-Related Disease (IgG4-RD) Prevalent Population in France
    • 4.4.2. IgG4-Related Disease (IgG4-RD) Diagnosed Prevalent Population in France
    • 4.4.3. IgG4-RD Gender-specific Prevalent Population in France
    • 4.4.4. Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in France
  • 4.5. Italy
    • 4.5.1. IgG4-Related Disease (IgG4-RD) Prevalent Population in Italy
    • 4.5.2. IgG4-Related Disease (IgG4-RD) Diagnosed Prevalent Population in Italy
    • 4.5.3. IgG4-RD Gender-specific Prevalent Population in Italy
    • 4.5.4. Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in Italy
  • 4.6. Spain
    • 4.6.1. IgG4-Related Disease (IgG4-RD) Prevalent Population in Spain
    • 4.6.2. IgG4-Related Disease (IgG4-RD) Diagnosed Prevalent Population in Spain
    • 4.6.3. IgG4-RD Gender-specific Prevalent Population in Spain
    • 4.6.4. Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in Spain
  • 4.7. United Kingdom
    • 4.7.1. IgG4-Related Disease (IgG4-RD) Prevalent Population in the United Kingdom
    • 4.7.2. IgG4-Related Disease (IgG4-RD) Diagnosed Prevalent Population in the United Kingdom
    • 4.7.3. IgG4-RD Gender-specific Prevalent Population in the United Kingdom
    • 4.7.4. Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in the United Kingdom
  • 4.8. Japan
    • 4.8.1. Assumptions and Rationale
    • 4.8.2. IgG4-Related Disease (IgG4-RD) Prevalent Population in Japan
    • 4.8.3. IgG4-Related Disease (IgG4-RD) Diagnosed Prevalent Population in Japan
    • 4.8.4. IgG4-RD Gender-specific Prevalent Population in Japan
    • 4.8.5. Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in Japan

5. Appendix

  • 5.1. Report Methodology

6. DelveInsight Capabilities

7. Disclaimer

8. About DelveInsight

List of Tables

  • Table 1 IgG4-Related Disease Total Population in the 7MM (2017-2028)
  • Table 2 IgG4-Related Disease Total Diagnosed Population in the 7MM (2017-2028)
  • Table 3 IgG4-RD Prevalent Population of IgG4-RD in the United States (2017-2028)
  • Table 4 IgG4-RD Diagnosed Prevalent Population in the United States (2017-2028)
  • Table 5 IgG4-RD Gender-specific Prevalent Population in the United States (2017-2028)
  • Table 6 Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in the United States (2017-2028)
  • Table 7 IgG4-RD Prevalent Population of IgG4-RD in Germany (2017-2028)
  • Table 8 IgG4-RD Diagnosed Prevalent Population in Germany (2017-2028)
  • Table 9 IgG4-RD Gender-specific Prevalent Population in Germany (2017-2028)
  • Table 10 Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in Germany (2017-2028)
  • Table 11 IgG4-RD Prevalent Population of IgG4-RD in France (2017-2028)
  • Table 12 IgG4-RD Diagnosed Prevalent Population in France (2017-2028)
  • Table 13 IgG4-RD Gender-specific Prevalent Population in France (2017-2028)
  • Table 14 Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in France (2017-2028)
  • Table 15 IgG4-RD Prevalent Population of IgG4-RD in Italy (2017-2028)
  • Table 16 IgG4-RD Diagnosed Prevalent Population in Italy (2017-2028)
  • Table 17 IgG4-RD Gender-specific Prevalent Population in Italy (2017-2028)
  • Table 18 Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in Italy (2017-2028)
  • Table 19 IgG4-RD Prevalent Population of IgG4-RD in Spain (2017-2028)
  • Table 20 IgG4-RD Diagnosed Prevalent Population in Spain (2017-2028)
  • Table 21 IgG4-RD Gender-specific Prevalent Population in Spain (2017-2028)
  • Table 22 Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in Spain (2017-2028)
  • Table 23 IgG4-RD Prevalent Population of IgG4-RD in the United Kingdom (2017-2028)
  • Table 24 IgG4-RD Diagnosed Prevalent Population in the United Kingdom (2017-2028)
  • Table 25 IgG4-RD Gender-specific Prevalent Population in the United Kingdom (2017-2028)
  • Table 26 Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in the United Kingdom (2017-2028)
  • Table 27 IgG4-RD Prevalent Population of IgG4-RD in Japan (2017-2028)
  • Table 28 IgG4-RD Diagnosed Prevalent Population in Japan (2017-2028)
  • Table 29 IgG4-RD Gender-specific Prevalent Population in Japan (2017-2028)
  • Table 30 Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in Japan (2017-2028)

List of Figures

  • Figure 1 Pathogenesis of IgG4-RD
  • Figure 2 Comprehensive diagnostic criteria for IgG4-RD
  • Figure 3 Diagnostic algorithm for IgG4-RD
  • Figure 4 IgG4-Related Disease Total Population in the 7MM (2017-2028)
  • Figure 5 IgG4-Related Disease Total Diagnosed Population in the 7MM (2017-2028)
  • Figure 6 IgG4-RD Prevalent Population of IgG4-RD in the United States (2017-2028)
  • Figure 7 IgG4-RD Diagnosed Prevalent Population in the United States (2017-2028)
  • Figure 8 IgG4-RD Gender-specific Prevalent Population in the United States (2017-2028)
  • Figure 9 Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in the United States (2017-2028)
  • Figure 10 IgG4-RD Prevalent Population of IgG4-RD in Germany (2017-2028)
  • Figure 11 IgG4-RD Diagnosed Prevalent Population in Germany (2017-2028)
  • Figure 12 IgG4-RD Gender-specific Prevalent Population in Germany (2017-2028)
  • Figure 13 Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in Germany (2017-2028)
  • Figure 14 IgG4-RD Prevalent Population of IgG4-RD in France (2017-2028)
  • Figure 15 IgG4-RD Diagnosed Prevalent Population in France (2017-2028)
  • Figure 16 IgG4-RD Gender-specific Prevalent Population in France (2017-2028)
  • Figure 17 Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in France (2017-2028)
  • Figure 18 IgG4-RD Prevalent Population of IgG4-RD in Italy (2017-2028)
  • Figure 19 IgG4-RD Diagnosed Prevalent Population in Italy (2017-2028)
  • Figure 20 IgG4-RD Gender-specific Prevalent Population in Italy (2017-2028)
  • Figure 21 Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in Italy (2017-2028)
  • Figure 22 IgG4-RD Prevalent Population of IgG4-RD in Spain (2017-2028)
  • Figure 23 IgG4-RD Diagnosed Prevalent Population in Spain (2017-2028)
  • Figure 24 IgG4-RD Gender-specific Prevalent Population in Spain (2017-2028)
  • Figure 25 Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in Spain (2017-2028)
  • Figure 26 IgG4-RD Prevalent Population of IgG4-RD in the United Kingdom (2017-2028)
  • Figure 27 IgG4-RD Diagnosed Prevalent Population in the United Kingdom (2017-2028)
  • Figure 28 IgG4-RD Gender-specific Prevalent Population in the United Kingdom (2017-2028)
  • Figure 29 Autoimmune Pancreatitis (AIP) Diagnosed Prevalent Population in the United Kingdom (2017-2028)
  • Figure 30 IgG4-RD Prevalent Population of IgG4-RD in Japan (2017-2028)
  • Figure 31 IgG4-RD Diagnosed Prevalent Population in Japan (2017-2028)
  • Figure 32 IgG4-RD Gender-specific Prevalent Population in Japan (2017-2028)
  • Figure 33 Treatment algorithm for IgG4-RD
Back to Top